definiens: is defined in Section 12.3(a);(e ) is defined in Section 12.3;(f ) means the prevention, treatment or mitigation of any disease via theadministration of a Pharmaceutical Agent that is not a peptide and that in a predictable model ofApoA - I expression, using either a human or nonhuman primate model, is demonstrated to have atleast a seven percent ( 7 % ) increase in humans and fifty percent ( 50 % ) increase in nonhumanprimates in the ApoA-1 plasma level in two consecutive weeks of treatment using less than 30milligrams – b.i.d . ( 60 milligrams per day ) of the Pharmaceutical Agent per kilogram of theweight of the subject;(g ) means information about the Disclosing Party 's business oractivities, which shall include business information, financial, technical, compositions, processes, techniques, research, developments, studies, reports and other data pertaining to the DisclosingParty ; provided that information shall not be considered Confidential Information of a Party if itcan be shown from documented records that such information:(i ) was known to the Receiving Party on the date of disclosure directly or indirectly from asource other than one having an obligation of confidentiality to the Disclosing Party;(ii ) hereafter becomes known ( independently of disclosure by the Disclosing Party ) to theReceiving Party directly or indirectly from a source other than one having an obligationof confidentiality to the Disclosing Party;(iii ) is, or becomes, publicly known or otherwise ceases to be confidential, except through abreach of this Agreement by the Receiving Party, or(iv ) was independently developed by the Receiving Party without use of any of theConfidential Information;(h ) is defined in Section 14.1;(i ) means an application of a Method or a Pharmaceutical Agent that iswithin the scope of both a Residual Field and the ApoA - I Therapeutic Field, whether such dualscope is known at the Effective Date or at any time thereafter